CSIMarket
 


Alkermes Plc   (ALKS)
Other Ticker:  
 
 

ALKS's Revenue Growth by Quarter and Year

Alkermes Plc 's Revenue results by quarter and year




ALKS Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - 304.67 324.46 280.00
III Quarter September 380.94 252.36 294.14 265.01
II Quarter June 617.40 276.22 303.72 247.53
I Quarter March 287.60 278.55 251.43 246.22
FY   1,285.94 1,111.80 1,173.75 1,038.76



ALKS Revenue third quarter 2023 Y/Y Growth Comment
Alkermes Plc achieved in the third quarter 2023, above Company average Revenue rise of 50.95% year on year, to $ 380.94 millions.

Looking into third quarter 2023 results within Major Pharmaceutical Preparations industry 4 other companies have achieved higher Revenue growth. While Alkermes Plc ' s Revenue jump of 50.95% ranks overall at the positon no. 353 in the third quarter 2023.




ALKS Revenue ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - -6.1 % 15.88 % -32.16 %
III Quarter September 50.95 % -14.2 % 10.99 % 3.83 %
II Quarter June 123.52 % -9.05 % 22.7 % -11.56 %
I Quarter March 3.25 % 10.79 % 2.12 % 10.36 %
FY   - -5.28 % 13 % -11.29 %

Financial Statements
Alkermes Plc 's third quarter 2023 Revenue $ 380.94 millions ALKS's Income Statement
Alkermes Plc 's third quarter 2022 Revenue $ 252.36 millions Quarterly ALKS's Income Statement
New: More ALKS's historic Revenue Growth >>


ALKS Revenue (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - 20.73 % 10.31 % 5.66 %
III Quarter September -38.3 % -8.64 % -3.15 % 7.06 %
II Quarter June 114.67 % -0.84 % 20.8 % 0.53 %
I Quarter March -5.6 % -14.15 % -10.2 % -40.34 %
FY (Year on Year)   - -5.28 % 13 % -11.29 %




Revenue third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #5
Healthcare Sector #29
Overall #353

Revenue Y/Y Growth Statistics
High Average Low
40.56 % 9.85 % -12.57 %
(Sep 30 2023)   (Mar 31 2021)
Revenue third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #5
Healthcare Sector #29
Overall #353
Revenue Y/Y Growth Statistics
High Average Low
40.56 % 9.85 % -12.57 %
(Sep 30 2023)   (Mar 31 2021)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Alkermes Plc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
114.68 % 2.72 % -100 %
(Jun 30 2023)  


ALKS's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2023 Alkermes Plc reported fall in Revenue from the previous quarter by -38.3% to $ 380.94 millions, from $ 617.40 millions released a quarter before.

If you evaluate current downturn at the III. Quarter, you should presume, that frequently III. Quarter Revenue emerge weaker in contrast to the quarter before

Within Major Pharmaceutical Preparations industry 219 other companies have achieved higher Revenue quarter on quarter growth. While Alkermes Plc 's Revenue growth quarter on quarter, overall rank is 3826.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #220
Healthcare Sector #591
Overall #3826
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #220
Healthcare Sector #591
Overall #3826
Revenue Q/Q Growth Statistics
High Average Low
114.68 % 2.72 % -100 %
(Jun 30 2023)  


ALKS's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2023 Alkermes Plc disclosed fall in Revenue sequentially by -38.3% to $ 380.94 millions, from $ 617.40 millions released a quarter before.

As we look into present slump at the III. Quarter, we must presume, that frequently III. Quarter performance occur sluggish in contrast to the preciding period, Wilmer Larsson, Major Pharmaceutical Preparations industry researcher situated in Frankfurt said.

Within Major Pharmaceutical Preparations industry 219 other companies have achieved higher Revenue quarter on quarter growth. While Alkermes Plc 's Revenue growth quarter on quarter, overall rank is 3826.


Alkermes Plc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative Revenue 12 Months Ending $ 1,590.60 $ 1,462.02 $ 1,120.85 $ 1,111.80 $ 1,131.58
Y / Y Revenue Growth (TTM) 40.56 % 24.6 % -6.66 % -5.28 % 0.2 %
Year on Year Revenue Growth Overall Ranking # 315 # 121 # 140 # 1087 # 1024
Seqeuential Revenue Change (TTM) 8.79 % 30.44 % 0.81 % -1.75 % -3.56 %
Seq. Revenue Growth (TTM) Overall Ranking # 353 # 2637 # 316 # 1624 # 1201




Cumulative Revenue growth Comment
With 40.56% annual Revenue growth, Alkermes Plc would report a record annual Revenue growth if the fiscal year would end on Sep 30 2023.

Within the Healthcare sector 23 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 121 to 315.

Revenue TTM Q/Q Growth Statistics
High Average Low
40.56 %
9.85 %
-12.57 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 5
Healthcare Sector # 24
Overall # 315

Revenue TTM Y/Y Growth Statistics
High Average Low
40.56 %
9.85 %
-12.57 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 5
Sector # 29
S&P 500 # 353
Cumulative Revenue growth Comment
With 40.56% annual Revenue growth, Alkermes Plc would report a record annual Revenue growth if the fiscal year would end on Sep 30 2023.

Within the Healthcare sector 23 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 121 to 315.

Revenue TTM Q/Q Growth Statistics
High Average Low
40.56 %
9.85 %
-12.57 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 5
Healthcare Sector # 24
Overall # 315

Revenue TTM Y/Y Growth Statistics
High Average Low
40.56 %
9.85 %
-12.57 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 5
Sector # 29
S&P 500 # 353




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ALKS's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for ALKS's Competitors
Revenue Growth for Alkermes Plc 's Suppliers
Revenue Growth for ALKS's Customers

You may also want to know
ALKS's Annual Growth Rates ALKS's Profitability Ratios ALKS's Asset Turnover Ratio ALKS's Dividend Growth
ALKS's Roe ALKS's Valuation Ratios ALKS's Financial Strength Ratios ALKS's Dividend Payout Ratio
ALKS's Roa ALKS's Inventory Turnover Ratio ALKS's Growth Rates ALKS's Dividend Comparisons



Companies with similar Revenue growth for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2023
Evoke Pharma Inc 87.82%$ 87.821 millions
Xoma Corporation84.04%$ 84.035 millions
Catalyst Pharmaceuticals Inc 79.39%$ 79.386 millions
Esperion Therapeutics inc 78.97%$ 78.973 millions
Docgo Inc 78.83%$ 78.828 millions
Precision Biosciences Inc78.19%$ 78.188 millions
Marpai Inc 76.77%$ 76.771 millions
Bicycle Therapeutics Plc76.05%$ 76.053 millions
Intra cellular Therapies Inc 75.56%$ 75.557 millions
Agilon Health Inc 74.95%$ 74.951 millions
Rxsight Inc 72.26%$ 72.263 millions
Elite Pharmaceuticals Inc 71.86%$ 71.860 millions
Procept Biorobotics Corporation71.38%$ 71.379 millions
Pacific Biosciences Of California Inc 69.92%$ 69.917 millions
Biocardia Inc68.40%$ 68.396 millions
Xtant Medical Holdings Inc 68.26%$ 68.262 millions
Cvrx inc67.98%$ 67.978 millions
Merus N v 67.65%$ 67.649 millions
Alimera Sciences Inc 66.25%$ 66.245 millions
Coherus Biosciences inc 64.16%$ 64.160 millions
C4 Therapeutics Inc 63.93%$ 63.932 millions
Y mabs Therapeutics inc 63.15%$ 63.149 millions
Nanostring Technologies Inc 62.79%$ 62.787 millions
Xeris Biopharma Holdings Inc 62.56%$ 62.557 millions
Adma Biologics Inc 62.21%$ 62.211 millions
Acadia Pharmaceuticals Inc 61.96%$ 61.956 millions
Orthofix Medical Inc 61.20%$ 61.201 millions
Molecular Templates inc 60.28%$ 60.283 millions
Sintx Technologies Inc 59.15%$ 59.155 millions
Ani Pharmaceuticals Inc57.27%$ 57.274 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com